This press release contains "forward-looking" statements, including, without limitation, statements related to plans to pursue further clinical development of R788 (fostamatinib), including the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "estimate," "anticipate" and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with the timing and success of clinical trials and other risks detailed from time to time in Rigel's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.
Media Contacts: Tracy Knudsen, AstraZeneca, Mobile: +32-472-900-803, Email: tracy.knudsen@astrazeneca.com; Raul Rodriguez, Rigel Office: +1-650-624-1302, Email: invrel@rigel.com; Susan C. Rogers, Alchemy Consulting, Inc. (for Rigel), Office: +1-650-430-3777, Email: susan@alchemyemail.com
